Abstract
Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small cell lung cancer (NSCLC) and in combination with cisplatin in treatment of malignat pleural mesothelioma. It has been studied in numerous phase II and III trials in combination with different drugs or as single agent. Recently, pemetrexed has been approved in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than squamous cell histology. The toxicity is acceptable and similar to that of other NSCLC regimens. The postinduction maintenance therapy with pemetrexed is being evaluated in a phase III, double-blind, placebo-controlled study.
| Original language | English |
|---|---|
| Pages (from-to) | 781-787 |
| Number of pages | 7 |
| Journal | Therapeutics and Clinical Risk Management |
| Volume | 5 |
| Issue number | 1 |
| Publication status | Published - 2009 |
Fingerprint
Keywords
- First-line setting
- Non-small cell lung cancer
- Non-squamous carcinoma
- Pemetrexed
ASJC Scopus subject areas
- Pharmacology (medical)
- Medicine(all)
- Pharmacology, Toxicology and Pharmaceutics(all)
- Safety Research
- Chemical Health and Safety
Cite this
Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer. / Ricciardi, Serena; Tomao, Silverio; De Marinis, Filippo.
In: Therapeutics and Clinical Risk Management, Vol. 5, No. 1, 2009, p. 781-787.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer
AU - Ricciardi, Serena
AU - Tomao, Silverio
AU - De Marinis, Filippo
PY - 2009
Y1 - 2009
N2 - Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small cell lung cancer (NSCLC) and in combination with cisplatin in treatment of malignat pleural mesothelioma. It has been studied in numerous phase II and III trials in combination with different drugs or as single agent. Recently, pemetrexed has been approved in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than squamous cell histology. The toxicity is acceptable and similar to that of other NSCLC regimens. The postinduction maintenance therapy with pemetrexed is being evaluated in a phase III, double-blind, placebo-controlled study.
AB - Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small cell lung cancer (NSCLC) and in combination with cisplatin in treatment of malignat pleural mesothelioma. It has been studied in numerous phase II and III trials in combination with different drugs or as single agent. Recently, pemetrexed has been approved in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than squamous cell histology. The toxicity is acceptable and similar to that of other NSCLC regimens. The postinduction maintenance therapy with pemetrexed is being evaluated in a phase III, double-blind, placebo-controlled study.
KW - First-line setting
KW - Non-small cell lung cancer
KW - Non-squamous carcinoma
KW - Pemetrexed
UR - http://www.scopus.com/inward/record.url?scp=77949458607&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77949458607&partnerID=8YFLogxK
M3 - Article
C2 - 19851525
AN - SCOPUS:77949458607
VL - 5
SP - 781
EP - 787
JO - Therapeutics and Clinical Risk Management
JF - Therapeutics and Clinical Risk Management
SN - 1176-6336
IS - 1
ER -